LLY

1,130.08

+0.44%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

AZN

185.95

+2.31%↑

LLY

1,130.08

+0.44%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

AZN

185.95

+2.31%↑

LLY

1,130.08

+0.44%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

AZN

185.95

+2.31%↑

LLY

1,130.08

+0.44%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

AZN

185.95

+2.31%↑

LLY

1,130.08

+0.44%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

AZN

185.95

+2.31%↑

Home・Akciju saraksts・Johnson and Johnson

Johnson and Johnson

Slēgts

SektorsVeselības aprūpe

232.65 1.91

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

228.24

Max

235.18

Galvenie mērījumi
By Trading Economics
Ienākumi	119M 5.2B
Pārdošana	-502M 24B
P/E Sektora vidējais	25.899 49.888
EPS	2.7
Dividenžu ienesīgums	2.31
Peļņas marža	21.756
Darbinieki	138,200
EBITDA	182M 6.4B

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+16.76% upside

Dividendes
By Dow Jones
Dividenžu ienesīgums Sektora vidējais	2.31% 2.38%
Nākamie ieņēmumi	2026. g. 15. jūl.
Nākamais dividenžu datums	2026. g. 9. jūn.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-35B 538B
Iepriekšējā atvēršanas cena	230.74
Iepriekšējā slēgšanas cena	232.65

Ziņu noskaņojums

By Acuity

22%

78%

45 / 344 Rangs Healthcare

Johnson and Johnson Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 24. apr. 13:27 UTC

Iegādes, apvienošanās, pārņemšana

Johnson & Johnson to Acquire Atraverse Medical to Bolster Cardiac Device Portfolio

2026. g. 23. apr. 21:48 UTC

Iegādes, apvienošanās, pārņemšana

Regeneron Shares Up on Trump Drug Pricing Deal -- Barrons.com

2026. g. 22. apr. 11:27 UTC

Peļņas

Intuitive Surgical Earnings Show Big Beats Don't Always Spark Stock Rallies -- Barrons.com

2026. g. 14. apr. 19:38 UTC

Peļņas

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

2026. g. 14. apr. 14:13 UTC

Peļņas

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

2026. g. 14. apr. 12:57 UTC

Peļņas

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

2026. g. 14. apr. 11:19 UTC

Peļņas

Johnson & Johnson Beats Earnings Estimates. Cancer Treatments Help Drive the Quarter. -- Barrons.com

2026. g. 14. apr. 10:34 UTC

Peļņas

Johnson & Johnson Stock Rises on Earnings Beat. These Segments Boosted the Quarter. -- Barrons.com

2026. g. 14. apr. 10:20 UTC

Tirgus saruna

Peļņas

J&J Sees Path to Double-Digit Growth by End of Decade -- Market Talk

2026. g. 14. apr. 10:20 UTC

Tirgus saruna

Peļņas

J&J's Tremfya Sales Continue to Surge -- Market Talk

2026. g. 14. apr. 10:20 UTC

Peļņas

Johnson & Johnson: With MedTech, Anticipate Additional Rounds of VBP in China Throughout Year, Heavier in Second Half of Year >JNJ

2026. g. 14. apr. 10:20 UTC

Peļņas

Johnson & Johnson: Expect Heavier Investment in First Half of 2026 Year >JNJ

2026. g. 14. apr. 10:20 UTC

Peļņas

Johnson & Johnson: With Innovative Medicine, Expect More Pronounced Sales Impact From Newly Launched Products as 2026 Progresses>JNJ

2026. g. 14. apr. 10:20 UTC

Peļņas

Johnson & Johnson Announce Planned Enterprise Business Review for Dec. 8, 2026 >JNJ

2026. g. 14. apr. 10:20 UTC

Peļņas

Johnson & Johnson: Anticipate Higher EPS Growth in Second Half of Year Vs First Half >JNJ

2026. g. 14. apr. 10:20 UTC

Peļņas

Johnson & Johnson: With MedTech, Expect Continued Acceleration of Newly Launched Products as Year Progresses With Normalized Seasonality >JNJ

2026. g. 14. apr. 10:20 UTC

Peļņas

Johnson & Johnson: With MedTech, Surgery Transformation Sales Headwinds Expected to Increase Through Year >JNJ

2026. g. 14. apr. 10:20 UTC

Peļņas

Johnson & Johnson Sees 2026 Adjusted Operational EPS $11.30-$11.50 Vs Prior View $11.28-$11.48 >JNJ

2026. g. 14. apr. 10:20 UTC

Peļņas

Johnson & Johnson: Anticipate Fairly Consistent Operational Sales Growth in First and Second Half With 53rd Week Affecting Second Half >JNJ

2026. g. 14. apr. 10:20 UTC

Peļņas

Johnson & Johnson: With Innovative Medicine, Anticipate Generic Competition for Opsumit (Second Half in U.S.) and Simponi (First Half in EU; Potentially Second Half in U. S.) >JNJ

2026. g. 14. apr. 10:20 UTC

Peļņas

Johnson & Johnson Sees 2026 Adj. Operational Sales Growth in Range of 5.6%-6.6% Vs Prior View 5.4%-6.4% >JNJ

2026. g. 14. apr. 10:20 UTC

Peļņas

Johnson & Johnson: 1Q Innovative Medicine Operational Sales Growth Driven Primarily by Darzalex, Carvykti, Erleada, Rybrevant/Lazcluze, Tremfya and Spravato >JNJ

2026. g. 14. apr. 10:20 UTC

Peļņas

Johnson & Johnson Raises 2026 View To Sales $100.3B-$101.3B Vs Prior View $100B-$101B >JNJ

2026. g. 14. apr. 10:20 UTC

Peļņas

Johnson & Johnson 1Q Orthopaedics Sales $2.38B >JNJ

2026. g. 14. apr. 10:20 UTC

Peļņas

Johnson & Johnson: 1Q MedTech Business Growth Driven Primarily by Electrophysiology Products, Abiomed, Shockwave as Well as Trauma >JNJ

2026. g. 14. apr. 10:20 UTC

Peļņas

Johnson & Johnson Sees 2026 Operational Sales of $99.7B-$100.7B Vs Prior View $99.5B-$100.5B>JNJ

2026. g. 14. apr. 10:20 UTC

Peļņas

Johnson & Johnson 1Q Adj EPS $2.70 >JNJ

2026. g. 14. apr. 10:20 UTC

Peļņas

Johnson & Johnson: New Treatment for Bladder Cancer Inlexzo Is Outperforming All Recent Launches Based on Unique Patients Treated in First 6 Months of Approval >JNJ

2026. g. 14. apr. 10:20 UTC

Peļņas

Johnson & Johnson 1Q U.S. Sales $13.33B >JNJ

2026. g. 14. apr. 10:20 UTC

Peļņas

Johnson & Johnson 1Q International Sales $10.73B >JNJ

Salīdzinājums

Cenas izmaiņa

Johnson and Johnson Prognoze

Cenas mērķis

By TipRanks

16.76% augšup

Prognoze 12 mēnešiem

Vidējais 266.4 USD 16.76%

Augstākais 285 USD

Zemākais 250 USD

Pamatojoties uz 17 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Johnson and Johnson — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

17 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 17 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Johnson and Johnson — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

45 / 344 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Johnson and Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company has a collaboration agreement with Stand Up To Cancer for research testing a combination of teclistamab and daratumumab to treat a rare disease AL amyloidosis. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.